Teva North America Tracks Millions of Products Across the Entire Supply Chain for Improved Safety and Business Insight
Oracle 1-800-633-0738
Find an Oracle Specialized Partner
Oracle Customer Programs

Teva North America Tracks Millions of Products Across the Entire Supply Chain for Improved Safety and Business Insight

  • Oracle Customer:  Teva North America
    Location:  North Wales, Pennsylvania
    Industry:  Life Sciences
    Employees:  9,000
    Annual Revenue:  Over $5 Billion

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is a leading global pharmaceutical company, committed to providing consumers with access to high-quality healthcare by developing, producing, and marketing affordable generic, innovative, and specialty products, as well as active pharmaceutical ingredients. The world’s largest maker of generic pharmaceutical products, Teva has a global product portfolio of more than 1,300 molecules and a direct presence in approximately 60 countries. The company’s branded businesses focus on products for the central nervous system, oncology, pain, respiratory, women’s health, and biologics.

Teva North America is comprised of subsidiaries of Teva Pharmaceutical Industries Ltd. The North American group has locations in 13 states, the District of Columbia, Canada, and Puerto Rico, and more than 9,000 employees.




A word from Teva North America

  • "Oracle Fusion Middleware and Oracle E-Business Suite are critical components of our e-pedigree solution—enabling us to optimize our existing technology investment. We’ve created a robust and highly scalable solution that will enable us to track our products across the entire pharmaceutical supply chain—improving safety and giving business insight into inventory, costs, and quality assurance.” – Jagadish Shivaramaiah, Manager, Applications Development, Teva North America

  • Comply with State of California and other emerging e-pedigree anticounterfeiting initiatives that require pharmaceutical manufacturers to apply unique serial numbers to track products at the unit, case, and pallet levels, tracing serial number movement across trading partners and through the entire pharmaceutical supply chain
  • Create an e-pedigree solution that scales and can introduce a standardized serialization process across a global organization that has grown significantly through mergers
  • Leverage the compliance infrastructure to advance broader business objectives, such as greater supply chain agility, tighter inventory control, and more efficient distribution
  • Ensure that the e-pedigree solution integrates with existing infrastructure and key trading partners to optimize current IT investment


  • Used Oracle Fusion Middleware components, Oracle E-Business Suite, and a third-party traceability server, warehouse management system, and packaging execution system to create a scalable and robust e-pedigree solution that satisfies immediate regulatory requirements and positions the company for future business benefits
  • Laid a foundation to enable consumers in the future to know the exact path and chain of custody that their pharmaceutical products have taken, from point of production, to the pharmacy, guarding against counterfeiting and ensuring safety
  • Built a platform that will enable Teva to integrate serialized information with additional business transactions and processes―such as inventory control, quality assurance, returns, pricing, and contracts―for greater insight into operations
  • Positioned the organization to obtain a real-time picture of where more than 1.5 million pharmaceutical products are at any point in the supply chain, which enables tighter inventory control, especially in short-supply situations, and drives better understanding of the impact of disruptions or process changes—ultimately supporting better decision-making
  • Gained the ability to determine the exact cost of each unit, from manufacture through consumption, and monitor market manipulation, improving competitive position
  • Used Oracle SOA Suite to integrate the flow of information between manufacturing resource planning, enterprise resource planning, serialization, and warehouse management systems to ensure complete documentation and full traceability
  • Enabled the new serialization and legacy enterprise systems to co-exist, thanks to Oracle SOA Suite, which supports a loosely coupled approach to integration
  • Allowed business processes to operate across a multinode network, thanks to Oracle SOA Suite, which makes the integration process more fault-tolerant and protects existing investments against potential business and technological disruption
  • Optimized existing technology investments as part of the e-pedigree initiative, speeding development, reducing investment costs, and minimizing business risk
  • Created a highly scalable solution that is capable of supporting massive data volumes and real-time data exchange between systems, including processing and printing billions of serial numbers and then storing the history of each unit

Why Oracle

Teva North America evaluated several middleware solutions, including IBM WebSphere, when it launched its e-pedigree initiative. “We conducted a thorough evaluation of solutions, and Oracle led the pack in terms of its roadmap, following the acquisition of WebLogic. It also provided strong benchmarks, and we had resources in house that were experienced with Oracle’s solution set, including Oracle E-Business Suite,” said Jagadish Shivaramaiah, manager, applications development, Teva North America.

Implementation Process

Teva’s e-pedigree solution―which required four years to build and test―was a ground-breaking initiative involving the integration of numerous systems as well as the deployment of new technologies. For the North American initiative, Teva used Oracle SOA Suite to integrate the company’s Northwest US Distribution Center, packaging lines throughout North America, and downstream trading partners.

After piloting in the United Sates, Teva will roll out its e-pedigree solution at its manufacturing facilities across the globe over the next 18-to-24 months.